All Title Author
Keywords Abstract

Publish in OALib Journal
ISSN: 2333-9721
APC: Only $99

ViewsDownloads

Low Dose Indomethacin in the Outpatient Treatment of COVID-19 in Kidney Transplant Recipients—A Case Series

DOI: 10.4236/oalib.1106860, PP. 1-8

Subject Areas: Nephrology

Keywords: Coronavirus Disease (COVID-19), Kidney Transplant Recipient, Indomethacin

Full-Text   Cite this paper   Add to My Lib

Abstract

The pandemic caused by the coronavirus SARS-CoV-2 has affected millions of people around the world. There are no definitive treatments available to date, which has led to the use of several repurposed drugs. Indomethacin is an effective non-steroidal anti-inflammatory drug, which has played an important role in the treatment of rheumatological conditions and cytokine storms, in the past. Coronavirus disease 2019 (COVID-19) causes cytokine storm and multiorgan dysfunction resulting in high mortality in those affected. Kidney transplant recipients are susceptible to COVID-19, which has caused a higher mortality than the general population, due to the immunosuppressed state. Twelve kidney transplant recipients under regular follow up at our hospital, consulted over the telephone, if they had features of COVID-19. Low dose indomethacin in this group of patients was given in those who were assessed to have mild disease and could be managed at home. Four of twelve patients were admitted to hospital due to their worsening symptoms. However, none of them died and all the 12 patients made good recovery at the end of 4 weeks. This has resulted in not only treating their symptoms, but probably also prevented more hospitalizations by avoiding or attenuating a cytokine storm in them. Indomethacin could prove to be a useful drug in the treatment of mild COVID-19, in view of its easy availability, low cost and minimal side effects.

Cite this paper

Kanakaraj, A. and Ravichandran, R. (2020). Low Dose Indomethacin in the Outpatient Treatment of COVID-19 in Kidney Transplant Recipients—A Case Series. Open Access Library Journal, 7, e6860. doi: http://dx.doi.org/10.4236/oalib.1106860.

References

[1]  Abolghasemi, S., Mardani, M., Sali, S., Honarvar, N. and Baziboroun, M. (2020) COVID-19 and Kidney Transplant Recipients. Transplant Infectious Disease, e13413. https://doi.org/10.1111/tid.13413
[2]  Nair, V., Jandovitz, N., Hirsch, J.S., et al. (2020) COVID-19 in Kidney Transplant Recipients. American Journal of Transplantation, 20, 1819-1825. https://doi.org/10.1111/ajt.15967
[3]  Karuthu, S. and Blumberg, E.A. (2012) Common Infections in Kidney Transplant Recipients. Clinical Journal of the American Society of Nephrology, 7, 2058-2070. https://doi.org/10.2215/CJN.04410512
[4]  Alberici, F., Delbarba, E., Manenti, C., et al. (2020) Management of Patients on Dialysis and with Kidney Transplant during SARS-COV-2(COVID-19) Pandemic in Brescia, Italy. Kidney International Reports, 5, 580-585. https://doi.org/10.1016/j.ekir.2020.04.001
[5]  Kute, V., Varugese, S., Prasad, N., Shroff, S. and Agarwal, S.K. (2020) On Behalf of COVID-19 Working Group of Indian Society of Nephrology Renal Transplant Guidelines with Reference to COVID-19 Infection. Indian Journal of Nephrology, 30, 176-178. https://doi.org/10.4103/ijn.IJN_221_20
[6]  Amici, C., Di Caro, A., Ciucci, A., et al. (2006) Indomethacin Has a Potent Antiviral Activity against SARS Coronavirus. Antiviral Therapy, 11, 1021-1030.
[7]  Amici, C., La Frazia, S., Brunelli, C., Balsamo, M., Angelini, M. and Santoro, M.G. (2015) Inhibition of Viral Protein Translation by Indomethacin in Vesicular Stomatitis Virus Infection: Role of elF2α Kinase PKR. Cellular Microbiology, 17, 1391-1404. https://doi.org/10.1111/cmi.12446
[8]  Marinella, M.A. (2020) Indomethacin and Resveratrol as Potential Treatment Adjuncts for SARS-CoV2/COVID-19. International Journal of Clinical Practice, 74, e13535. https://doi.org/10.1111/ijcp.13535
[9]  Rudd, P. and Rudd, P. (1992) Indomethacin and Nifedipine Reduced Coughing Induced by Captopril Therapy. ACP Journal Club, 117, 42. http://www.acpjournals.org/doi/abs/10.7326/ACPJC-1992-117-2-042
[10]  Verdecchia, P., Cavallini, C., Spanevello, A. and Angeli, F. (2020) The Pivotal Link between ACE2 Deficiency and SARS-Cov-2 Infection. European Journal of Internal Medicine, 76, 14. https://doi.org/10.1016/j.ejim.2020.04.037
[11]  Banerjee, D, Popoola, J., Shah, S., Ster, I.C., Quan, V. and Phanish, M. (2020) COVID-19 Infection in Kidney Transplant Recipients. Kidney International, 97, 1076-1082. https://doi.org/10.1016/j.kint.2020.03.018
[12]  Devresse, A., Belkhir, L., Vo, B., et al. (2020) COVID-19 Infection in Kidney Transplant Recipients: A Single Center Case Series of 22 Cases from Belgium. Kidney Medicine, 2, 459-466. https://doi.org/10.1016/j.xkme.2020.06.001
[13]  Nair, V., Jandovitz, N., Hirsch, J.S., et al. (2020) COVID-19 in Kidney Transplant Recipients. American Journal of Transplantation, 20, 1819-1825. https://doi.org/10.1111/ajt.15967
[14]  Elias, M., Pievani, D., Randoux, C., et al. (2020) COVID-19 Infection in Kidney Transplant Recipients: Disease Incidence and Clinical Outcomes. Journal of the American Society of Nephrology, 31, 2413-2423. https://doi.org/10.1681/ASN.2020050639

Full-Text


comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

微信:OALib Journal